Generics key to Lupin’s future growth


Lupin, one of the most consistent performers in the pharma sector, reported lower-than-expected revenue growth for the third quarter due to sluggishness in its overseas businesses. However, given a strong pipeline of new drug applications and a diversified geographical presence, the company’s long-term prospects look strong. In the forthcoming quarters, key generic launches in the US will be one of the major growth drivers for Lupin. The company has over 97 abbreviated new drug applications pending approval -one-third of these are the first to file applications (bearing 180day exclusive marketing rights).

Read the source article at The Economic Times

About the Author

Leave a Reply